CRDL — Cardiol Therapeutics Share Price
0.000.00%
Last trade - 00:00- CA$168.66m
- CA$133.90m
- 21
- 11
- 89
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.97 | ||
| Price to Tang. Book | 6.02 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -104.86% | ||
| Return on Equity | -69.93% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | 0.08 | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.
Directors
- Guillermo Torre-Amione CHM
- David Elsley PRE
- Chris Waddick CFO
- Bernard Lim COO
- Anthony Bolton OTH
- Andrew Hamer OTH (54)
- Thomas Moffatt OTH
- Iain Chalmers DRC
- Michael Willner DRC (63)
- Peter Pekos IND
- Colin Stott IND
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 19th, 2017
- Public Since
- December 20th, 2018
- No. of Employees
- 17
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 68,283,708
- Address
- 602-2265 Upper Middle Road East, OAKVILLE, L6H 0G5
- Web
- https://www.cardiolrx.com/
- Phone
- +1 2899100850
- Contact
- Trevor Burns
- Auditors
- BDO Canada LLP
Upcoming Events for CRDL
Cardiol Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Cardiol Therapeutics Inc Earnings Release
Similar to CRDL
AEterna Zentaris
Toronto Stock Exchange
Antibe Therapeutics(Pre-Merger)
Toronto Stock Exchange
Appili Therapeutics
Toronto Stock Exchange
Aptose Biosciences
Toronto Stock Exchange
Avicanna
Toronto Stock Exchange
FAQ
What is the Cardiol Therapeutics share price?
As of Today at 19:04 UTC, shares in Cardiol Therapeutics are trading at CA$2.47. This share price information is delayed by 15 minutes.
How has the Cardiol Therapeutics share price performed this year?
Shares in Cardiol Therapeutics last closed at CA$2.47 and the price had moved by +225% over the past 365 days. In terms of relative price strength the Cardiol Therapeutics share price has outperformed the Toronto Stock Exchange 300 Composite Index by +208.39% over the past year.
What are the analyst and broker recommendations for Cardiol Therapeutics?
The overall consensus recommendation for Cardiol Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cardiol Therapeutics dividend yield?
Cardiol Therapeutics does not currently pay a dividend.
Does Cardiol Therapeutics pay a dividend?
Cardiol Therapeutics does not currently pay a dividend.
When does Cardiol Therapeutics next pay dividends?
Cardiol Therapeutics does not currently pay a dividend.
How do I buy Cardiol Therapeutics shares?
To buy shares in Cardiol Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cardiol Therapeutics?
As of the previous close price of CA$2.47, shares in Cardiol Therapeutics had a market capitalisation of CA$168.66m.
Where are Cardiol Therapeutics shares listed?
Here are the trading details for Cardiol Therapeutics:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: CRDL
What kind of share is Cardiol Therapeutics?
Based on an overall assessment of its quality, value and momentum Cardiol Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cardiol Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Cardiol Therapeutics is CA$4.05. That is 63.97% above the last closing price of CA$2.47.
Analysts covering Cardiol Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.47 for the next financial year.
What is the trend in the Cardiol Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cardiol Therapeutics. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +129.5%.
As of the last closing price of CA$2.47, shares in Cardiol Therapeutics were trading +64.72% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cardiol Therapeutics PE Ratio?
The Cardiol Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$2.47.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cardiol Therapeutics?
Cardiol Therapeutics' management team is headed by:
- Guillermo Torre-Amione - CHM
- David Elsley - PRE
- Chris Waddick - CFO
- Bernard Lim - COO
- Anthony Bolton - OTH
- Andrew Hamer - OTH
- Thomas Moffatt - OTH
- Iain Chalmers - DRC
- Michael Willner - DRC
- Peter Pekos - IND
- Colin Stott - IND